This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus (CXL)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Peschke Meditrade, GmbH.
Recruitment status was:  Not yet recruiting
Information provided by:
Peschke Meditrade, GmbH Identifier:
First received: June 19, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
This is a compassionate treatment protocol for the use of the UV-X system for corneal collagen cross-linking (CXL) in eyes with progressive keratoconus in patients who have conditions that limit their capacity to comply with the cross-linking treatment procedures required by ongoing clinical trials.

Condition Intervention Phase
Progressive Keratoconus Other: Corneal collagen cross-linking with riboflavin/UVA light Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Peschke Meditrade, GmbH:

Primary Outcome Measures:
  • Change in keratometry [ Time Frame: 3 Months ]

Secondary Outcome Measures:
  • Change in manifest refraction spherical equivalent [ Time Frame: 3 Month ]

Estimated Enrollment: 7
Arms Assigned Interventions
Experimental: Corneal collagen cross-linking with riboflavin and UVA light Other: Corneal collagen cross-linking with riboflavin/UVA light
Corneal collagen cross-linking with riboflavin/UVA light

Detailed Description:
This is a non-randomized study. All eyes that qualify for the study will receive the cross-linking (CXL) procedure. Corneal collagen cross-linking is performed as a single treatment. Depending on the patient's condition, the CXL procedure may be performed under sedation or anesthesia. Subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collagen cross-linking.

Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 6 to 18 years
  • Having a diagnosis of progressive keratoconus
  • Signed written informed consent
  • Having a condition that limits the patient's capacity to comply with the cross-linking treatment procedures and/or the diagnostic tests and measurements required by the ongoing clinical studies
  • Willingness and ability to comply with schedule for follow-up visits

Exclusion Criteria:

  • Corneal pachymetry at the screening exam that is <400 microns at the thinnest point
  • Previous ocular condition in the eye(s) to be treated that may predispose the eye for future complications, for example (herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, or corneal dystrophy, etc.)
  • A history of delayed epithelial healing in the eye(s) to be treated
  • Pregnancy or lactation during the course of the study
  • A known sensitivity to study medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00925327

Contact: Erin D. Stahl, MD 816-234-3046

United States, Missouri
Children's Mercy Hospitals and Clinics Not yet recruiting
Kansas City, Missouri, United States, 65108
Contact: Erin D. Stahl, MD    816-234-3046      
Principal Investigator: Scott E. Olitsky, MD         
Sub-Investigator: Erin D. Stahl, MD         
Sponsors and Collaborators
Peschke Meditrade, GmbH
  More Information

Responsible Party: Rudi Peschke, Peschke Meditrade GmbH Identifier: NCT00925327     History of Changes
Other Study ID Numbers: UVX-004
Study First Received: June 19, 2009
Last Updated: June 19, 2009

Additional relevant MeSH terms:
Corneal Diseases
Eye Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents processed this record on September 20, 2017